skip to Main Content

Pelareorep/Atezolizumab Plus Chemo Shows Early Safety in Frontline Metastatic Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
The 3-patient safety run-in for the pancreatic cancer cohort of the ongoing phase 1/2 GOBLET study did not reveal any safety concerns with the novel combination of pelareorep and atezolizumab (Tecentriq).1

As such, the study, which is evaluating different pelareorep combination regimens in patients with metastatic pancreatic, metastatic colorectal, and advanced anal cancers, has been recommended to continue as planned. The safety run-in for the third-line metastatic colorectal cancer (CRC) cohort is ongoing. Read more . . . 


Back To Top